Article

Electrochemically Enhanced Delivery of Pemetrexed from Electroactive Hydrogels

Sophie Au-Yong 1,†, Melike Firlak 1,2,†, Emily R. Draper 3, Sofia Municoy 4 ♦, Mark D. Ashton 1, Geoffrey R. Akien 1, Nathan R. Halcovitch 1 ♦, Sara J. Baldock 1, Pierre Martin-Hirsch 5, Martin F. Desimone 4 ♦ and John G. Hardy 1,6,∗

1 Department of Chemistry, Faraday Building, Lancaster University, Lancaster LA1 4YB, UK
2 Department of Chemistry, Gebze Technical University, Gebze 41400, Turkey
3 School of Chemistry, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK
4 Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Facultad de Farmacia y Bioquímica, Consejo Nacional de Investigaciones, Científicas y Técnicas (CONICET), Universidad de Buenos Aires, Junín 956, Piso 3◦ (1113), Buenos Aires 1113, Argentina
5 Lancashire Teaching Hospitals NHS Trust, Royal Preston Hospital, Sharoe Green Lane, Preston PR2 9HT, UK
6 Materials Science Institute, Lancaster University, Lancaster LA1 4YB, UK
∗ Correspondence: j.g.hardy@lancaster.ac.uk
† These authors contributed equally to this work.

Abstract: Electroactive hydrogels based on derivatives of polyethyleneglycol (PEG), chitosan and polypyrrole were prepared via a combination of photopolymerization and oxidative chemical polymerization, and optionally doped with anions (e.g., lignin, drugs, etc.). The products were analyzed with a variety of techniques, including: FT-IR, UV-Vis, 1H NMR (solution state), 13C NMR (solid state), XRD, TGA, SEM, swelling ratios and rheology. The conductive gels swell ca. 8 times less than the non-conductive gels due to the presence of the interpenetrating network (IPN) of polypyrrole and lignin. A rheological study showed that the non-conductive gels are soft (G' 0.35 kPa, G'' 0.02 kPa) with properties analogous to brain tissue, whereas the conductive gels are significantly stronger (G' 30 kPa, G'' 19 kPa) analogous to breast tissue due to the presence of the IPN of polypyrrole and lignin. The potential of these biomaterials to be used for biomedical applications was validated in vitro by cell culture studies (assessing adhesion and proliferation of fibroblasts) and drug delivery studies (electrochemically loading the FDA-approved chemotherapeutic pemetrexed and measuring passive and stimulated release); indeed, the application of electrical stimulus enhanced the release of PEM from gels by ca. 10–15% relative to the passive release control experiment for each application of electrical stimulation over a short period analogous to the duration of stimulation applied for electrochemotherapy. It is foreseeable that such materials could be integrated in electrochemotherapeutic medical devices, e.g., electrode arrays or plates currently used in the clinic.

Keywords: hydrogels; stimuli-responsive; biomedical engineering; drug delivery

1. Introduction

Biologically active compounds have been used for several thousand years to prolong and improve life (e.g., pain relief, vaccines, etc.) [1,2]. It is important to note that the biological activity of drugs can be reduced before they reach the desired cells due to degradation via enzymes and low absorption rates, and polymeric matrices can enhance the delivery of such compounds. Drug delivery via needles/tablets/etc. tends to result in burst release profiles and undesired side effects due to the delivery of the bioactive to otherwise healthy cells/organisms/tissues [3], and systems capable of precisely controlling the delivery of compounds offer opportunities for innovation in healthcare systems worldwide (e.g., improving patient compliance, minimizing unwanted side effects, etc.) [3,4]. Stimuli-responsive drug delivery systems that can trigger the release of their payloads upon
exposure to bio-/physico-chemical cues (e.g., enzymes [5], light [6], pH [7], temperature [8]), are capable of releasing a controlled amount of drug when desired.

Electrically triggered release systems offer a high degree of control of quantity/rate of release, potential for integration in existing medical devices (e.g., electrodes for sensing/stimulation, implants, etc.) and with instrumentation capable of controlling the delivery systems [9]. Such delivery systems can be easily miniaturized, and controlled/powered remotely [9,10], or indeed using sacrificial power sources [11], in various materials morphologies [12]. Polypyrrole (PPy) is one of the most widely investigated conducting polymers applied to drug delivery matrices due to its biocompatibility, low voltage actuation and ease of synthesis [13]. A variety of other conducting polymers (including polyaniline (PANI) and poly(3,4-ethylenedioxythiophene) (PEDOT)) have been investigated for their application in the development of controlled drug delivery systems [14,15]. The drug/biomolecule loading and release process depends on electrostatic interactions between the electroactive polymer and charged molecules which can be tuned by modulating the applied voltage and time of the electric stimulation, with potential for incorporation of low and high molecular weight drugs [10].

Polymer-based hydrogels are popular for biomedical applications, particularly in the development of tissue scaffolds and drug delivery systems because the polymer networks are swollen with water [16,17] facilitating transport of nutrients/waste from tissue scaffolds and bioactive payloads for drug delivery systems [18,19]. The appeal is also driven by the variety of polymers available (particularly PEG [20,21]) methods for the preparation of 3D hydrogels (e.g., chemical/photochemical/in situ crosslinking) and ease with which it is possible to tailor the properties (e.g., pore size distribution, swelling ability, mechanical properties, etc.) of the resulting hydrogels to meet the requirements of specific biomedical applications [22,23].

Polysaccharides are a class of abundant biopolymers [24,25] that are degradable (e.g., enzymatically/hydrolytically) [26], non-immunogenic [27], and a variety of polysaccharide-based biomaterials have been clinically translated [28–30]. Chitosan (CS) is one example of a polysaccharide, which is a partially deacetylated derivative of chitin, which displays amines [31] that can be used to facilitate crosslinking, either in situ or to attach other polymerizable species to (e.g., methacrylates) [32]. CS has been widely used in the development of hydrogel-based biomaterials [33–35]. Lignins are another class of abundant biopolymers that display antibiotic and anti-fungal activity [36,37], which motivates their inclusion in biomaterials.

Conducting polymers are a class of stimuli-responsive polymers that have potential for use in biomedical applications (e.g., neural electrodes, drug delivery systems, etc.) [38,39] and technical applications (e.g., diodes, sensors, transistors, etc.) [40–42], and are therefore interesting for integration in gels. Conducting polymers (e.g., polyaniline (PANI), polypyrrole (PPy) and poly(3,4-ethylenedioxythiophene) (PEDOT)) have been implanted in vivo for long periods of time with minimal inflammatory response (analogous to FDA-approved poly(lactic-co-glycolic acid), PLGA) [43], which can be integrated into existing medical devices [44,45], and it is possible to generate degradable versions of them [46]. Doping conducting polymers with high molecular weight may tune the mechanical properties of the materials [47,48] or indeed cell responses to the surfaces of the biomaterials [49]. Conducting polymer-based drug delivery systems respond to electrical stimuli and function by mechanisms including actuation, charge passage, redox switching, etc. [50] enabling precise spatiotemporal control of the amount of drugs of various molecular weights [51–55].

Conducting polymer-based electrode coatings enable delivery of drugs in the proximity of the site at which the electrodes are implanted, which is potentially impactful for electrochemotherapy which functions by electroproporation of the cancerous tissue shortly after injection of anticancer drugs such as bleomycin or cisplatin [56–60]. Electrochemotherapy functions through a variety of mechanisms, including: the cytotoxic effect of the chemotherapeutic which is enhanced by electroporation; vasoconstriction of tumor blood vessel for several hours due to sympathetic nerve stimulation which reduces drug washout...
from the tumor; vascular disruption due to cytotoxicity towards the endothelial cells of
tumor blood vessels; the immune response to immunogenic cell death and enhanced tumor
antigen expression [61–63]. Electrochemotherapy has been used to enhance the delivery
of a variety of drugs [59,60,64–68], and has been observed to be a swift, safe and effective
treatment method for cancers that tends to enhance the quality of life of patients [69–73].

Here, we describe the development of electroactive hydrogels composed of PEG, CS,
PPy and lignin (serving as both a reinforcing agent and dopant for PPy) that were produced
via a combination of photopolymerization and oxidative chemical polymerization; the PPy
in the hydrogels was doped with anions (e.g., lignins, drugs). The materials were analyzed
by a variety of techniques including: FT-IR, UV-Vis, $^1$H NMR (solution state), $^{13}$C NMR
(solid state), SEM, XRD, TGA, swelling ratios and rheology. In silico and in vitro methods
were employed to validate the potential application of the materials for biomedical appli-
cations, exemplified by drug delivery studies for the FDA-approved chemotherapeutic
pemetrexed (PEM). Such hydrogels could be used as coatings for medical devices, for ex-
ample, as coatings for electrodes used for electrochemotherapy for cancer treatment [74,75],
wherein triggered release of an anticancer drug directly into the cancerous tissue would
potentially be more effective and diminish unwanted side effects enhancing the patient’s
quality of life.

2. Materials and Methods

Unless otherwise noted, all chemicals and consumables were purchased from either
Sigma Aldrich (St. Louis, MO, USA) or Thermo Fisher (Waltham, MA, USA), of analytical
grade, and used without further purification/modification.

2.1. Synthesis

2.1.1. Preparation of Polymerizable CS Derivatives

CS (2 g, medium molecular weight, estimated 75–85% deacetylation) was added to
water (200 mL), to which pyrrole-2-carboxylic acid (1 g, 9 mmol) and methacrylic acid
(0.76 mL, 0.78 g, 9 mmol) was added, and the mixture was stirred vigorously until the CS
dissolved. N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 3.8 g,
19.8 mmol) and N-hydroxysuccinimide (NHS, 2.8 g, 19.8 mmol) were added to the solution
by stirring for 24 h at room temperature in the dark. The modified CS was purified by
dialysis (MWCO 3500) against deionized (DI) water for 3 days (changing the water at least
4 times per day), followed by lyphophilization for 4 days. The pink/purple solid product
was isolated in a quantitative yield (2.1 g). This was combined with other components to
prepare hydrogels using the formulations in Table 1.

Table 1. Formulations used for the preparation of non-conductive and conductive gels.

| Component       | Non-Conductive Gels | Conductive Gels |
|------------------|----------------------|-----------------|
| Water            | 1 mL                 | 1 mL            |
| PEGDA            | 50 mg                | 50 mg           |
| Modified CS derivative | 4.5 mg   | 4.5 mg          |
| Lignin           | N/A                  | 100 mg          |
| Pyrrole          | N/A                  | 200 µL          |

2.1.2. Preparation of Non-Conductive Hydrogels

A solution of modified CS in DI water (0.45 wt%) was stirred until homogenous. The
photoinitiator 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure-2959)
was added at 0.1 wt% to the solution of CS derivative; and PEG-diacrylate (PEGDA,
Mn 2000) was added at 5 wt%. This mixture was stirred in the dark for ca. 2 h until
homogenous. Silicone isolators (molds) produced by Grace Bio-Labs (Sigma Aldrich)
(9 mm in diameter × 0.8 mm in depth) were placed onto clean glass slides. 75 µL of gel
precursor solution was added to each well and irradiated for 1 h under a Mega LV202E
UV exposure unit (with 2 × 8 W bulbs, output from ~300–460 nm, peak at 365 nm), and
the reaction mixture was left in the molds overnight. The hydrogels were left in DI water for 24 h to remove unreacted monomers and low molecular weight contaminants with periodic changes of water (typically 3 to 4 times per day), after which they were transferred to fresh water for another 24 h.

2.1.3. Preparation of Conductive Hydrogels

A solution of modified CS in DI water (0.45 wt%) was stirred until homogenous. The photoinitiator 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropophenone (Irgacure-2959) was added at 0.1 wt% to the solution of CS derivative; and PEG-diacrylate (PEGDA, Mn 2000) was added at 5 wt%. Pyrrole (200 µL, 4.3 mmol per mL of PEGDA-modified CS) was purified by passage through an alumina column added to 1 mL of PEGDA-modified CS with lignin (lignin alkali, low sulfonate content, 100 mg/mL), and this mixture was stirred in the dark for ca. 2 h until homogenous. Silicone isolators (molds) produced by Grace Bio-Labs (Sigma Aldrich) (9 mm in diameter × 0.8 mm in depth) were placed onto clean glass slides. 75 µL of gel precursor solution was added to each well and irradiated for 1 h under a Mega LV202E UV exposure unit (with 2 × 8W bulbs, output from ~300–460 nm, peak at 365 nm), and the reaction mixture was left in the molds overnight. Ferric chloride (FeCl₃, 1 wt%) was dissolved in water and the gels were left to incubate for 24 h, after which the supernatant was decanted and the samples were washed thoroughly with DI water until the water became clear and colorless (typically 72 h to remove unreacted monomers and low molecular weight contaminants with periodic changes of water, typically 3 to 4 times per day), after which they were transferred to fresh water for another 24 h.

2.2. Characterization

2.2.1. UV-Vis Spectroscopy

UV-vis spectra were recorded using a Thermo Scientific NanoDrop 2000. CS was dissolved in an aqueous solution of acetic acid (1% v/v) whereas the other samples were in DI water.

2.2.2. Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy

An Agilent Technologies Infrared Spectrometer was used to record spectra in ATR mode in the range of 4000–500 cm⁻¹. The data was exported to the software supplied by the manufacturer (ResPro) and the baseline was corrected.

2.2.3. Solution State ¹H NMR Spectroscopy

¹H NMR spectra were recorded with a Bruker AVANCE III 400 (NanoBay) equipped with a 5 mm ¹H-X broadband observe (BBO, ¹⁰⁹Ag-¹⁹F) RT probe, and (3-trimethylsilyl)propionic-2,2,3,3-d₄ sodium salt was added as a reference in all samples. 5 mm NMR tubes (Norell standard series 5) were used for all samples. 1 mg of CS medium MW was dissolved in 1 mL of 2% DCl v/v (35 wt% in D₂O) in D₂O solution and heated to ~70 °C for an hour or until complete dissolution. For modified CS, the same procedure was followed however heating was not necessary. Acetic acid was dissolved in D₂O at a concentration of (5 mg/mL). Pyrrole-2-carboxylic acid was dissolved in DMSO-d₆ at a concentration of (5 mg/mL). The spectra of methacrylic acid was acquired in both D₂O and DMSO-d₆.

2.2.4. Solid State ¹³C NMR Spectroscopy

A Bruker AVANCE III HD 700 WB was used to record ¹³C NMR spectra via cross-polarization/magic angle spinning.

2.2.5. Scanning Electron Microscopy (SEM)

Prior to imaging the samples were lyophilized (FreeZone benchtop freeze dryer, Labconco™, Fisher Scientific, Loughborough, UK), then sputter coated with a 10 nm layer of gold using a Quorum 150R ES. A JEOL JSM-7800F field emission SEM (JEOL, Welwyn Garden City, UK) operating at 10–15 kV was used to obtain SEM images.
2.2.6. Conductivity Determination

The conductance of dried gels were measured in accordance with protocol IPC-TM-650, number 2.5.17.2 described by the Institute for Interconnecting and Packaging Electronic Circuits. Dried gels supported on glass slides were examined by chronoamperometry using a Keithley 2612B source meter (Tektronix, Beaverton, OR, USA). Chronoamperometric measurements were made with a two-point probe system (copper alligator clips), by connecting counter and reference electrodes together. Briefly, two thin strips of adhesive-backed copper tape (Ted Pella, Inc., Redding, CA, USA) were attached to the dried gels, parallel to one another, separated by a distance of 0.5 cm. The working and counter electrodes were clipped on the strips of copper tape, and the current measured for 30 s during a potential step experiment at 10 V. The electrodes were moved to different positions after each measurement, and the current passed was recorded at three different positions. The resistance \( R \) \( (\Omega) \) of the gels was determined by measurements of voltage \( V \) and current \( I \) in accordance with Equation (1):

\[
R = \frac{V}{I}
\]

(1)

The resistivity \( (\Omega \text{ cm}^{-1}) \) of the dried gels was determined in accordance with Equation (2):

\[
\rho = \frac{R w t}{L}
\]

(2)

In which: \( w \) corresponds to the width of the gel in cm (ca. 0.5 cm, determined on a sample-by-sample basis using digital calipers, Scienceware® Digi-Max™ slide calipers); \( t \) corresponds to the thickness of the dried gel in cm (as determined via profilometry); and \( L \) corresponds to the length of the gel in cm (ca. 0.5 cm, determined on a sample by sample basis using digital calipers). The conductivity \( (\text{S cm}^{-1}) \) of the gels was determined in accordance with Equation (3):

\[
\sigma = \frac{1}{\rho}
\]

(3)

2.2.7. X-ray Diffraction (XRD)

XRD patterns were recorded using a Rigaku SmartLab powder diffractometer with a 2\( \theta \) scattering range of 5 to 40\( ^\circ \) and a resolution of 0.1\( ^\circ \).

2.2.8. Thermogravimetric Analysis (TGA)

Thermal stability of vacuum dried hydrogels (ca. 4–5 mg) were observed with a NETZSCH STA 449 F3 Jupiter thermal analyser. Temperatures observed were from 25 to 550 \( ^\circ \text{C} \) with a heating rate of 10 \( ^\circ \text{C/min} \). The reference pan used was alumina.

2.2.9. Swelling Studies

The swelling ratio of the hydrogels was determined by recording the initial mass its dry state and the mass after swelling in PBS for 24 h (after removal of excess water by wicking with filter paper) at room temperature, and calculated using Equation (4), where \( m_t \) is the mass at the time \( t \) and \( m_0 \) represents the initial mass.

\[
\text{Swelling Ratio (\%)} = \frac{(m_t - m_0)}{m_0} \times 100
\]

(4)

2.2.10. Rheological Characterization

The rheological properties of the gels were assessed using an Anton Paar Physica MCR 302 rheometer fitted with a parallel plate with a diameter of 12.484 mm. Strain sweep experiments were employed with a constant frequency of 10 rad/s. Frequency sweeps were performed at 0.5% strain for non-conductive hydrogels and at 0.1% for conductive hydrogels.
2.3. In Silico and In Vitro Validation

2.3.1. In Silico Toxicity Screening Studies

In silico toxicity screening was carried out using Derek Nexus and Sarah Nexus (Derek Nexus: v. 6.0.1, Nexus: 2.2.2; Sarah Nexus: v. 3.0.0, Sarah Model: 2.0) supplied by Lhasa Limited, Leeds, UK. The SMILES code for Irgacure-2959 is C(COC1=CC=C(C=C1)C(C(C(C)O)=O)O; for a simplified PEG-diacylate it is C=CC(OCCOC(C=C)=O)=O; and for the modified CS derivative it is O7\[C@@H\](O\[C@@H\]5C(O\[C@@H\](O\[C@@H\]1C(O\[C@H\](C(C1O)N)O\[C@@H\]4C(O\[C@@H\](O\[C@@H\]2C(O\[C@H\](C(C2O)N)O\[C@@H\]3C(O\[C@@H\](O)C(C3O)N)CO)CO)C(C4O)NC(C6=CC=CN6)=O)CO)C(C(\[C@@H\](C7CO)O)O)N.

2.3.2. In Vitro Cell Culture Studies

The NIH3T3 fibroblast cell line was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal calf serum, 1% penicillin–streptomycin and 0.25 µg/mL Fungizone, under an atmosphere of 5% CO\textsubscript{2} at 37 °C. Cells were harvested using a trypsin–EDTA solution and the number of viable cells was counted with a Neubauer camera after staining with trypan blue. Fibroblast cells (1 × 10\textsuperscript{4} cells per well) were added on top of each material or to the wells of 24-well plate (in case of control cells), with 0.5 mL of cell culture medium and kept in a humidified 5% CO\textsubscript{2} atmosphere at 37 °C. The cell metabolic activity was measured by the colorimetric 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay after 1–7 days. Briefly, cell culture medium was removed and a solution of MTT in PBS 1X (5 mg/mL) was added to the cells and incubated at 37 °C for 4 h. Then, the MTT solution was discarded, samples were washed with PBS 1X and absolute ethanol was added. Finally, absorbance of the purple solution was measured at 570 nm and results were expressed as mean ± SD from triplicate experiments. For cell imaging, cells grown for 24 h were first fixed using 2.5% glutaraldehyde. After 20 min, samples were washed three times with PBS 1X and 0.1% Triton X-100 in PBS 1X containing 1% BSA was added to permeabilize the cells for 30 min. Samples were then washed with PBS 1X and 300 µL of Alexa 488 phalloidin were added for staining. Cells were incubated at 37 °C and protected from light for 30 min. After this, samples were washed with PBS 1X and the phalloidin-stained cells were finally examined by fluorescence microscopy using a 20X objective on an inverted microscope (Confocal—Zeiss—AxioObserver Z1 LSM710) [76–78].

2.3.3. In Vitro Drug Loading

Conductive hydrogels were electrochemically loaded with pemetrexed using an aqueous solution of 4 mL of 1 mM pemetrexed disodium 2.5 hydrate as the electrolyte bath. The hydrogels were secured on glassy carbon electrodes by the electrode lid with a hole cut out at the top (Figure S1). A 3 electrode cell was composed of a Ag/AgCl reference electrode, platinum mesh counter electrode and a glassy carbon electrode with the hydrogel. For 30 min a potential of 0.6 V was applied via chronoamperometry. 10 µL of the solution after drug loading was diluted down 4 times with distilled water and the concentration of PEM assessed via UV-Vis measurements at 225 nm (\lambda_{max} of PEM) from which the loading efficiency is assessed and the difference in the concentration of PEM before/after used to assign “100%” loading.

2.3.4. In Vitro Drug Delivery Studies

UV spectroscopy confirmed that there was no release of the gel constituents from the unloaded gels (e.g., lignin, modified CS, PPy) over the course of the experiments. For stimulated drug release, the drug was released at a potential of −0.6 V in 4 mL of PBS for 30 s every 10 min 3 times. At each time interval, 10 µL of the solution was frozen for storage prior to UV-Vis spectroscopy. Passive release of the drug was carried out by placing the electrodes with hydrogels in 4 mL PBS and 10 µL samples were taken every 11 min in line with the sampling frequency for the samples that were electrically stimulated.
At each time interval, 10 µL of the solution was frozen for storage prior to UV-Vis spectroscopy. The concentration of PEM assessed via UV-Vis measurements at 225 nm (λmax of PEM).

3. Results and Discussion
3.1. CS Modification and Characterization

Methacrylic acid and pyrrole-2-carboxylic acid were conjugated to the amines displayed on the backbone of CS (a white/off-white solid in the dry state) using water soluble carbodiimide (EDC/NHS) chemistry, after dialysis and lyophilization this yielded a pink/purple solid (Scheme 1).

\[
\begin{align*}
\text{CS} & \quad \text{Methacrylic acid} \quad \text{Pyrrole-2-carboxylic acid} \\
\text{CONH}_{2} & \quad \text{CONH}_{2} \quad \text{CONH}_{2} \\
\text{CONH}_{2} & \quad \text{CONH}_{2} \quad \text{CONH}_{2}
\end{align*}
\]

Scheme 1. Chemical modification of CS (conjugation of methacrylate and pyrrole moieties via EDC/NHS chemistry).

The UV-vis spectra of the starting materials and product are displayed in Figure 1; clear differences between the spectra can be identified, while CS has a maxima of 218 nm (owing to N-acetylglucosamine (GluNAc) and glucosamine (GlcN)), the modified CS has a broad peak at around 195 nm with two peaks at ~200 and 255 nm that are not present in the CS starting material which are attributed to the methacrylate and pyrrole moieties conjugated to the CS.

The FTIR spectra for the CS starting material and the modified CS are shown in Figure 2. CS shows a broad peak at 3354 cm\(^{-1}\) which corresponds to -OH stretching overlapping with -NH\(_2\) symmetric and asymmetric stretching bands; peaks occurring at 1649, 1527 cm\(^{-1}\) correspond to the amide I (C=O stretch) and amide II (N-H bend, C-N stretch) vibrations, respectively; the absorbance at 1566 cm\(^{-1}\) corresponds to the N-H bend of an amine group (i.e., deacetylated from chitin); multiple low intensity peaks at 1419, 1373, 1321 cm\(^{-1}\) are ascribed to C-H bending; the peak at 1149 cm\(^{-1}\) is characteristic of C-O-C ether bonds present in the backbone of CS; the sharp absorbances at 1020, 1057 cm\(^{-1}\) are C-O stretches in the alcohol groups. The spectrum of the modified CS shows increases in the intensity of the amide I, amide II peaks, and those ascribed to C-H bending and stretching confirming modification with methacrylate/pyrrole units. The spectrum for the conductive samples were very broad due to experimental limitations of the technique, including: optical contact between the sample and ATR apparatus, anomalous dispersion [79–81], and the fact they are broad band absorbers which resulted in broad spectra as we have observed in previous studies [82].
Figure 1. UV-Vis spectra of CS (solid black line), modified CS (grey line), pyrrole carboxylic acid (black dashed) and methacrylic acid (grey dashed).

Figure 2. FTIR spectra. Unmodified CS (black solid line); modified CS (black dashed line); non-conductive hydrogel (grey solid line); conductive hydrogel (grey dashed line).

Solution state $^1$H NMR spectra for the CS starting material and the modified CS derivative in DCl/D$_2$O are shown in Figure 3. The small peak at around 2.03 ppm is ascribed to the methyl group (-CH$_3$) attached to the N-alkylated GlcN residue. At 3.10 ppm a singlet represents H2, multiplet signals from 3.5 to 4 ppm are assigned to H3, H4, H5 and H6 of GlN. From the literature, typically the spectra would show a small peak around 4.28 ppm due to H1 of both GlN and the acetylated form [83,84]. Comparison of the peak integrals from H2-H6 (~3 to 4 ppm) which represent 6 protons to the integral of
the peak at 2.03 ppm which represents 3 protons enables estimation of the degree of acetylation of the CS (the partially deacetylated derivative of chitin) which was ca. 12% in this study, i.e., the unmodified CS used is around 88% deacetylated (similar to the supplier’s estimate of 75–85% deacetylation). The spectra for modified CS shows new chemical shifts corresponding to the new functional groups installed. The peak at 1.9 ppm is characteristic of the methyl group attached to the methacrylate (confirmed by the NMR spectra of methacrylic acid showing a peak at 1.9 ppm). Signals from ~5 to 6.5 ppm are assigned to the two protons connected to the double bond. A multiplet of peaks with low intensity can be seen between 7.9 and 8.1 ppm which are ascribed to pyrrole attached to the backbone of CS (albeit very difficult to integrate in comparison to methacrylate moieties). Two-dimensional $^1$H—$^1$H COSY NMR links methacrylate olefins (5.5–6 ppm) to the methyl at 1.9 ppm (Figure 4).

![Figure 3](image-url)

**Figure 3.** $^1$H solution state NMR spectra. (Bottom) Unmodified CS. (Top) Modified CS.

Solid State $^{13}$C NMR CP-MAS spectra were recorded. The spectrum of unmodified CS starting material is shown in Figure 5, and the chemical shifts in accordance with the literature [85–93]. The modified CS exhibits similar chemical shifts to CS, signals at 105, 83, 75, 61 and 58 ppm correspond to C1, C4, C3, C6, C2 (Figure 5); the peaks in both spectra corresponding to C-O and CH$_3$ (due to partial deacetylation and amide) appear at 174 and 24 ppm, respectively; the conjugation of pyrrole was confirmed by peaks for the $\alpha$-carbon and $\beta$-carbon at ca. 125 and 109–105 ppm [94–97], and previous research by Forsyth et al. explains the low frequency shoulder on the peak at 123 ppm exists due to $\beta$-carbons being partially oxidized as opposed to pure pyrrole [94–97]; the conjugation of methacrylate was confirmed by peaks 19 ppm (CH$_3$), 37 ppm (C-C tertiary carbons pendant to the polymer chain) and 140 ppm (C=C) in line with the literature [98]. The peak for the carbonyls (C=O) pendant on the polymer chain for the unmodified CS (ca. 175 ppm) was significantly broader after conjugation of the methacrylate and pyrrole derivatives (ca. 170–180 ppm) owing to the multitude of different amide environments generated by the conjugation reaction in line with the literature [99,100].
which is likely due to the high content of PEG and lignin in these materials.

The FTIR spectra for the non-conductive and conductive gels are shown in Figure 2. For the non-conductive gels, in addition to the peaks associated with the modified CS, the very strong peak at 1149 cm$^{-1}$ from C-H stretching in alkanes/ethers, a peak at ca. 1740 cm$^{-1}$ corresponding to C=O and CH$_3$ (due to partial deacetylation and amide) appear at 174 ppm. The modified CS exhibits similar chemical shifts to CS, signals at 105, 83, 75, 61 and 58 ppm correspond to C1, C4, C3, C6, C2 (Figure 5); the peaks in both spectra for the acrylates to the termini of the PEG chains, and the very strong peak at 1149 cm$^{-1}$ in cross-sectional images). The conductance of dried gels was observed to be of the order of $2.65 \times 10^{-9}$ S/cm for the dried CS-PEG gels, and $8.88 \times 10^{-7}$ S/cm for the PPy containing gels, similar, albeit somewhat lower than analogous PPy-containing materials [74,101,102], which is likely due to the high content of PEG and lignin in these materials.

Figure 3. 1H solution state NMR spectra. (Bottom) Unmodified CS. (Top) Modified CS.

Figure 4. $^1$H-$^1$H COSY solution state NMR spectra of modified CS.

Figure 5. $^{13}$C solid state NMR spectra. (Top) Unmodified CS; (Bottom) Modified CS. N.B. X-axis in ppm.

3.2. Hydrogel Preparation and Characterization

Non-conductive hydrogels composed of PEG and CS were prepared by photopolymerization of PEGDA and the modified CS derivative in an aqueous solution of the photoinitiator Irgacure-2959, followed by washing. Conductive hydrogels composed of PEG, CS, PPy and lignin were prepared by photopolymerization of PEGDA, the modified CS derivative, pyrrole and lignin in an aqueous solution of the photoinitiator Irgacure-2959, followed by exposure of the gels to FeCl$_3$ to polymerize the pyrrole (followed by extensive washing to remove low molecular weight species), yielding PPy doped with anionic lignin and chloride distributed throughout the gels an interpenetrating polymer network; the resultant self-supporting gels were black colored due to the presence of the PPy and lignin. SEM images (Figure S2) of the surfaces of non-conductive hydrogels are smooth on the µm scale by comparison with the conductive hydrogels due to the particles of lignin-doped PPy embedded within the conductive gels (the PPy particles were also observed to be distributed throughout the gel matrix as a sample spanning interpenetrating network of PPy in cross-sectional images). The conductance of dried gels was observed to be of the order of $2.65 \times 10^{-9}$ S/cm for the dried CS-PEG gels, and $8.88 \times 10^{-7}$ S/cm for the PPy containing gels, similar, albeit somewhat lower than analogous PPy-containing materials [74,101,102], which is likely due to the high content of PEG and lignin in these materials.
The FTIR spectra for the non-conductive and conductive gels are shown in Figure 2. For the non-conductive gels, in addition to the peaks associated with the modified CS, the peaks associated with PEG (the major component of the non-conductive gels) are notable, with a strong band between 2960–2770 cm$^{-1}$ from C-H stretching in alkanes/ethers, a peak at ca. 1740 cm$^{-1}$ corresponding to the C=O stretch of the ester bonds that attach the methacrylates to the termini of the PEG chains, and the very strong peak at 1149 cm$^{-1}$ is characteristic of C-O-C ether bonds present in the backbone of PEG. The spectrum of conductive gels is different from the non-conductive gels, and all peaks are notably broader which is representative of the complex nature of the interpenetrating network of different polymeric species (PEG, CS, PPy and lignin). XRD patterns of the non-conductive gels and conductive gels suggested they were amorphous, confirmed by the peak at $2\theta \approx 23^\circ$ for the non-conductive gels and at $2\theta \approx 25^\circ$ for the conductive gels (Figure S3). TGA of dried gels (Figure S4) confirmed the presence of traces of water in the gels (mass loss between 45–180 °C). The non-conductive hydrogels began to degrade at ca. 200°C, and the majority of mass occurred between 200 °C and 380 °C in line with the literature [103]; by comparison, the conductive hydrogels degraded between 260 °C and 500 °C in line with the literature [104], implying the interpenetrating network enhances thermal stability. The TGA profiles suggest the compositions of the conductive gels to be ca. 30% PEG/CS and 70% PPy/lignin.

In principle this may enable sterilization by steam in an autoclave at 121 °C for 20 min, although there may be consequences for the mechanical/electrical properties of the hydrogels [105] and optimization of sterilization will be dependent upon the specific application of the hydrogels. The swell ratios of the non-conductive gels were ca. 1029 ± 327% whereas for the conductive gels it was ca. 123 ± 25%, suggesting that the interpenetrating network of anionic lignins and cationic CS/PPy in the conductive gels serve to further crosslink the gels.

The rheological properties of the hydrogels were characterized by both dynamic strain sweep testing (performed at a constant frequency of 1Hz (10 rad/s)) and frequency sweep testing (performed at 0.5% strain for non-conductive hydrogels and at 0.1% for conductive hydrogels) to assess the storage modulus ($G'$—elastic) and loss modulus ($G''$—viscous) of the hydrogels (Table 2 and Figure 6). When $G'$ is higher than $G''$ it suggests that the gel is highly structured and the material behaves in a solid-like fashion; the point where both moduli intersect signifies the breaking point of the hydrogels and is known as the critical strain level or gel point; as strain increases past the critical strain level, the network bonds start to break and the moduli both start to decline (when $G'$ drops below $G''$ the gel is more liquid-like) [106]. The properties for the non-conductive and conductive gels are summarized in Table 2.

| Variable       | Non-Conductive Gels (Wet) | Conductive Gels (Dry) | Conductive Gels (Wet) |
|----------------|----------------------------|-----------------------|-----------------------|
| $G'$           | 350 Pa                     | 650 Pa                | 30,000 Pa             |
| $G''$          | 22 Pa                      | 54 Pa                 | 19,000 Pa             |
| Yield point    | 15%                        | 7%                    | 0.8%                  |
| Flow point     | 95%                        | 140%                  | 4%                    |

The non-conductive gels are soft ($G'$ 0.35 kPa, $G''$ 0.02 kPa), with properties analogous to brain tissue; the conductive gels in the dry state are approximately twice as strong as the non-conductive hydrogels, and in the wet state the conductive gels are significantly stronger ($G'$ 30 kPa, $G''$ 19 kPa) analogous to breast tissue [107]. The differences in mechanical properties are likely due to intermolecular interactions between the interpenetrating network of anionic lignins and cationic CS/PPy in the conductive gels.
Figure 6. Rheology data. (A) strain sweep: non-conductive hydrogels (wet). (B) Frequency sweep: non-conductive hydrogels (wet). (C) strain sweep: conductive hydrogels (dry). (D) Frequency sweep: non-conductive hydrogels (dry). (E) strain sweep: conductive hydrogels (wet). (F) Frequency sweep: conductive hydrogels (wet).

3.3. In Silico and In Vitro Validation

We have previously examined the safety data sheets for (FeCl₃, pyrrole and polypyrrole) which report FeCl₃ to be a corrosive irritant that is toxic to aquatic life, and pyrrole is corrosive and could be toxic if swallowed (necessitating thorough washing to remove the
FeCl$_3$ and pyrrole), however, PPy and PSS are nontoxic; and employed in silico toxicity screening (Derek Nexus and Sarah Nexus) which demonstrated they were non-sensitizers of skin and non-mutagenic [101,108,109]. Here, we extend this approach to assessing the safety of the other components in the gels. The safety data sheets for unmodified CS and lignin suggest they are non-hazardous, whereas the PEG-diacrylate is a skin irritant/sensitizer and can cause serious eye damage, and the Irgacure-2959 may be toxic (LD50 Oral—Rat > 2000 mg/kg; LD50 Dermal—Rat [male and female] > 5000 mg/kg) [100,101], necessitating thorough washing to remove them after gel formation. Derek Nexus predicts that: Irgacure-2959 is non-mutagenic in vitro in bacterium (supported by Sarah Nexus) and a non-skin sensitizer in mammals; the modified CS is non-mutagenic in vitro in bacterium (supported by Sarah Nexus) and a plausible skin sensitizer and irritant in mammals (however, these are similar to unmodified CS, i.e., not due to the new functional groups attached), however, the new functional groups do render the modified CS derivative plausibly neurotoxic due to the acrylamide present after methacrylation [108–115]; the PEG-diacrylate is non-mutagenic in vitro in bacterium (supported by Sarah Nexus) and a plausible skin sensitizer and irritant in mammals, a plausible irritant of eyes/respiratory tracts in mammals, plausibly causes chromosome damage in vitro in mammals and unclear if it is carcinogenic in mammals. Clearly, as noted above the safety data sheets and in silico toxicity screening emphasize the necessity for thorough washing of the gels after production to remove any low molecular weight contaminants.

In vitro studies to assess the adhesion and proliferation of NIH3T3 fibroblasts on the hydrogels were conducted, using the standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to study cell adhesion and proliferation over the period of one week compared to the cells on tissue culture plastic, assessed at 1, 2, 3, 4 and 7 days. NIH3T3 fibroblasts adhered and proliferated on the non-conductive and conductive gels (no discernable differences between the data for the types of gel), albeit slightly less effectively on the gels than on the tissue culture plastic control (Figure 7).

![Figure 7. Cell adhesion/proliferation data.](image)

We studied the release of PEM from PEM-doped hydrogels into phosphate-buffered saline (PBS) in the absence/presence of electrical stimuli via UV spectroscopy (Figure 8) over the period of 30 min, a duration chosen as it is used in treatment of cancer via electrochemotherapy [59,60,66]. Passive release of PEM was observed from all hydrogels, however, this amounted to less than 5% over the course of the experiment, and the application of an electrical stimulus was observed to trigger the delivery of PEM from the gels,
with an increase of ca. 10–15% relative to the passive release control experiment for each application of electrical stimulation. This triggered release of PEM over the 30 min duration would be potentially useful for surgical procedures which may benefit from localized delivery of anticancer drugs, for example integration of these hydrogels as coatings on electrodes used for electrochemotherapy [74,75].

![Drug release profiles of hydrogels loaded with PEM. Without electrical stimulation (grey bars) and electrochemically triggered (black bars).](image)

The conductive hydrogels described herein are straightforward to prepare, with 1 synthetic step for the modified CS derivative, and a simple gel preparation protocol involving a photopolymerization step, followed by an oxidative polymerization step, followed by washing to remove non-crosslinked components. We foresee that the gel formulations and the protocols described could be adapted for 3D printing of bespoke 3D structures [116–118] with mechanical properties suitable for integration within a variety of soft human tissues [107]. It would be possible to incorporate and release a variety of different bioactive molecules with wide ranging molecular weights (including low molecular weight pharmaceuticals and high molecular weight biologics) depending on the specific tissue in which the biomaterials would be integrated [119,120]. The opportunity to precisely control the delivery of a payload is potentially very impactful where the chronobiology of the condition being treated is important [121,122].

4. Conclusions

The electroactive hydrogels described herein were prepared by a simple methodology, were robust enough to be handleable, and it is foreseeable they could be integrated into medical devices for the delivery of clinically relevant drugs. Such smart drug delivery systems represent a significant opportunity for patient-specific treatments in the future.

**Supplementary Materials:** The following supporting information can be downloaded at: [https://www.mdpi.com/article/10.3390/polym14224953/s1](https://www.mdpi.com/article/10.3390/polym14224953/s1), Figure S1: Side view (left) and top view (right) of set up for securing hydrogels on glassy carbon electrodes for drug delivery studies; Figure S2: SEM images (×1000 magnification). Top) non-conductive gels. Bottom) conductive gels. Scale bars represent 10 µm; Figure S3: X-ray diffractograms. Non-conductive gels (grey line); conductive gels (black line); Figure S4: TGA thermograms. Non-conductive hydrogels (grey); conductive hydrogels (black).

**Author Contributions:** Conceptualization, M.F. and J.G.H.; methodology, all authors; formal analysis, all authors; investigation, S.A.-Y., M.F., E.R.D., S.M., M.D.A., G.R.A., N.R.H., S.J.B.; data curation, M.F., E.R.D., S.M., M.D.A., G.R.A., N.R.H., S.J.B., M.F.D., J.G.H.; writing—original draft preparation, all authors; writing—review and editing, M.F., E.R.D., P.M.-H., M.F.D., J.G.H.; supervision, E.R.D., M.F.D., J.G.H.; project administration, M.F.D., J.G.H.; funding acquisition, M.F., M.F.D., J.G.H. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by a variety of sources, and we acknowledge: the UK Royal Society for support of J.G.H. (Grant reference: RG160449); the UK Royal Society Newton International Fellowship to support M.F. (Grant reference: NF151479), and the UK Royal Society and CONICET (Argentina) for supporting M.D.A., S.M., M.F.D. and J.G.H. (Grant reference: A10355); and UK Research and Innovation (UKRI) for support of E.R.D. (Grant reference: MR/V021087/1).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data available on reasonable request to the authors.

Acknowledgments: We thank Tekle Pauzaite and Nikki Copeland at Lancaster University for informative discussions.

Conflicts of Interest: The authors declare no conflict of interest.

The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the National Institute for Health Research (NIHR) or the Department of Health.

References

1. Mignani, S.; El Kazzouli, S.; Bousmina, M.; Majoral, J.P. Dendrimer space concept for innovative nanomedicine: A futuristic vision for medicinal chemistry. Prog. Polym. Sci. 2013, 38, 993–1008. [CrossRef]

2. Samuelsen, A.B. The traditional uses, chemical constituents and biological activities of Plantago major L. A review. J. Ethnopharmacol. 2000, 71, 1–21. [CrossRef]

3. Li, W.Q.; Guo, H.F.; Li, L.Y.; Zhang, Y.F.; Cui, J.W. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med. 2021, 10, 4677–4696. [CrossRef] [PubMed]

4. Grainger, D.W. Controlled-release and local delivery of therapeutic antibodies. Expert Opin. Biol. Ther. 2004, 4, 1029–1044. [CrossRef] [PubMed]

5. Kuang, T.R.; Liu, Y.R.; Gong, T.T.; Peng, X.F.; Hu, X.L.; Yu, Z.Q. Enzyme-responsive Nanoparticles for Anticancer Drug Delivery. Curr. Nanosci. 2016, 12, 38–46. [CrossRef]

6. Linsley, C.S.; Wu, B.M. Recent advances in light-responsive on-demand drug-delivery systems. Ther. Deliv. 2017, 8, 89–107. [CrossRef]

7. Yoshida, T.; Lai, T.C.; Kwon, G.S.; Sako, K. pH-and ion-sensitive polymers for drug delivery. Expert Opin. Drug Deliv. 2013, 10, 1497–1513. [CrossRef]

8. Bikram, M.; West, J.L. Thermo-responsive systems for controlled drug delivery. Expert Opin. Drug Deliv. 2008, 5, 1077–1091. [CrossRef]

9. Szunerits, S.; Teodorescu, F.; Boukherroub, R. Electrochemically triggered release of drugs. Eur. Polym. J. 2016, 83, 467–477. [CrossRef]

10. Guo, J.; Fan, D. Electrically Controlled Biochemical Release from Micro/Nanostructures for in vitro and in vivo Applications: A Review. ChemNanoMat 2018, 4, 1023–1038. [CrossRef]

11. Zhang, Z.N.; Zhang, R.; Rajagopalan, R.; Tang, Z.; Sun, D.; Wang, H.Y.; Tang, Y.G. A high-capacity self-sacrificial additive based on electroactive sodiated carbonyl groups for sodium-ion batteries. Chem. Commun. 2022, 58, 8702–8705. [CrossRef]

12. Zhao, Y.; Tavaresca, A.C.; Gauthier, M.A. Nano-engineered electro-responsive drug delivery systems. J. Mater. Chem. B 2016, 4, 3019–3030. [CrossRef]

13. Zinger, B.; Miller, L.L. Timed release of chemicals from polypyrrole films. J. Am. Chem. Soc. 1984, 106, 6861–6863. [CrossRef]

14. Kim, D.H.; Richardson-Burns, S.M.; Hendrickx, J.L.; Sequera, C.; Martin, D.C. Effect of Immobilized Nerve Growth Factor on Conductive Polymers: Electrical Properties and Cellular Response. Adv. Funct. Mater. 2007, 17, 79–86. [CrossRef]

15. Minisy, I.M.; Salahu-din, N.A.; Ayad, M.M. In vitro release study of ketoprofen-loaded chitosan/polyaniline nanofibers. Polym. Bull. 2020, 78, 5609–5622. [CrossRef]

16. Bolla, P.K.; Rodriguez, V.A.; Kalhapure, R.S.; Kolli, C.S.; Andrews, S.; Renukuntla, J. A review on pH and temperature responsive gels and other less explored drug delivery systems. J. Drug Deliv. Sci. Technol. 2018, 46, 416–435. [CrossRef]

17. Ruiz, A.L.; Ramirez, A.; McEnnis, K. Single and Multiple Stimuli-Responsive Polymer Particles for Controlled Drug Delivery. Pharmaceutics 2022, 14, 421. [CrossRef]

18. Shen, M.Y.; Yuran, S.; Aviv, Y.; Ayalew, H.; Luo, C.H.; Tsai, Y.H.; Reches, M.; Yu, H.H.; Shenhar, R. Electrically Responsive, Nanopatterned Surfaces for Triggered Delivery of Biologically Active Molecules into Cells. ACS Appl. Mater. Interfaces 2019, 11, 1201–1208. [CrossRef]

19. Peters, J.T.; Wechsler, M.E.; Peppas, N.A. Advanced biomedical hydrogels: Molecular architecture and its impact on medical applications. Regen. Biomater. 2021, 8, rhab060. [CrossRef]
20. Zhang, Y.Q.; Yu, J.C.; Kahkoska, A.R.; Wang, J.Q.; Buse, J.B.; Ga, Z. Advances in transdermal insulin delivery. *Adv. Drug Deliv. Rev.* 2019, 139, 51–70. [CrossRef]

21. Taghipour, Y.D.; Hokmabad, V.R.; Del Bakhshayesh, A.R.; Asadi, N.; Salehi, R.; Nasrabadi, H.T. The Application of Hydrogels Based on Natural Polymers for Tissue Engineering. *Curr. Med. Chem.* 2020, 27, 2658–2680.

22. Ghosh, S. Recent research and development in synthetic polymer-based drug delivery systems. *J. Chem. Res.* 2004, 4, 241–246. [CrossRef]

23. Peppas, N.A.; Bures, P.; Leobandung, W.; Ichikawa, H. Hydrogels in pharmaceutical formulations. *Eur. J. Pharm. Biopharm.* 2000, 50, 27–46. [CrossRef]

24. Gull, N.; Khan, S.M.; Islam, A.; Butt, M.T.Z. Hydrogels used for Biomedical Applications. In *Bio Monomers for Green Polymeric Composite Materials*, 1st ed.; Visakh, P.M., Bayraktar, O., Menon, G., Eds.; John Wiley & Sons Ltd.: Hoboken, NJ, USA, 2019; pp. 175–199.

25. Cascone, S.; Lambert, G. Hydrogel-based commercial products for biomedical applications: A review. *Int. J. Pharm.* 2020, 573, 118803. [CrossRef] [PubMed]

26. Shi, J.Y.; Yu, L.; Ding, J.D. PEG-based thermosensitive and biodegradable hydrogels. *Acta Biomater.* 2021, 128, 42–59. [CrossRef]

27. Alexander, A.; Ajazuddin, B.; Khan, J.; Saraf, S.; Saraf, S. Polyethylene glycol (PEG)-Poly(N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications. *Eur. J. Pharm. Biopharm.* 2014, 88, 575–585. [CrossRef]

28. Bashir, S.; Hina, M.; Iqbal, J.; Rajpar, A.H.; Mujtaba, M.A.; Alghamdi, N.A.; Wageh, S.; Ramesh, K.; Ramesh, S. Fundamental Concepts of Hydrogels: Synthesis, Properties, and Their Applications. *Polymers* 2020, 12, 2702. [CrossRef]

29. Li, Z.L.; Lin, Z.Q. Recent advances in polysaccharide-based hydrogels for synthesis and applications. *Aggregate 2021*, 2, e21. [CrossRef]

30. Liu, Z.H.; Jiao, Y.P.; Wang, Y.F.; Zhou, C.R.; Zhang, Z.Y. Polysaccharide-based nanoparticles as drug delivery systems. *Adv. Drug Deliv. Rev.* 2008, 60, 1650–1662. [CrossRef]

31. Garcia-Gonzalez, C.A.; Alnaief, M.; Smirnova, I. Polysaccharide-based aerogels-Promising biodegradable carriers for drug delivery systems. *Carbohydr. Polym.* 2011, 86, 1425–1438. [CrossRef]

32. Lei, K.; Li, Z.; Zhu, D.D.; Sun, C.Y.; Sun, Y.L.; Yang, C.C.; Zheng, Z.; Wang, X.L. Polysaccharide-based recoverable double-network hydrogel with high strength and self-healing properties. *J. Mater. Chem. B* 2020, 8, 794–802. [CrossRef]

33. Cheung, R.C.F.; Ng, T.B.; Wong, J.H.; Chan, W.Y. Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications. *Carbohydr. Polym.* 2015, 128, 23–39. [CrossRef]

34. Coviello, T.; Matricardi, F.; Marianeci, C.; Alhaique, F. Polysaccharide hydrogels for modified release formulations. *Adv. Drug Deliv. Rev.* 2007, 59, 119–139. [CrossRef]

35. Raveendran, S.; Yoshida, Y.; Maekawa, T.; Kumar, S. Pharmacetically versatile sulfated polysaccharide based bionano platforms. *Nanomed. Nanotechnol. Biol. Med.* 2013, 9, 605–626. [CrossRef]

36. Cheung, R.C.F.; Ng, T.B.; Wong, J.H.; Chan, W.Y. Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications. *Mar. Drugs* 2015, 13, 5156–5186. [CrossRef]

37. Zhang, Z.X.; Liow, S.S.; Xue, K.; Zhang, X.K.; Li, Z.B.; Loh, X.J. Autonomous Chitosan-Based Self-Healing Hydrogel Formed through Noncovalent Interactions. *ACS Appl. Polym. Mater.* 2019, 1, 1769–1777. [CrossRef]

38. Ahmad, F.; Oveisi, Z.; Samani, S.M.; Amoozgar, Z. Chitosan based hydrogels: Characteristics and pharmaceutical applications. *Res. Pharm. Sci.* 2015, 10, 1–16.

39. Pella, M.C.G.; Lima-Tenorio, M.K.; Neto, E.T.T.; Guilherme, M.R.; Muniz, E.C.; Rubira, A.F. Chitosan-based hydrogels: From preparation to biomedical applications. *Carbohydr. Polym.* 2018, 196, 233–245. [CrossRef]

40. Racine, L.; Texier, I.; Auzely-Velty, R. Chitosan-based hydrogels: Recent design concepts to tailor properties and functions. *Polym. Int.* 2017, 66, 981–998. [CrossRef]

41. Wang, J.; Vemmers, W. Antimicrobial Nanomaterials Derived from Natural Products-A Review. *J. Mater. 2016*, 9, 255. [CrossRef]

42. DellaGreca, M.; Zuppolini, S.; Zarrelli, A. Isolation of lignans as seed germination and plant growth inhibitors from Mediterranean plants and chemical synthesis of some analogues. *Phytochem. Rev.* 2013, 12, 717–731. [CrossRef]

43. Kim, S.; Jang, L.K.; Jang, M.; Lee, S.; Hardy, J.G.; Lee, J.Y. Electrically Conductive Polydopamine-Polypyrrole as High Performance Biomaterials for Cell Stimulation in Vitro and Electrical Signal Recording in Vivo. *ACS Appl. Mater. Interfaces* 2018, 10, 33032–33042. [CrossRef] [PubMed]

44. Hendricks, J.L.; Chikar, J.A.; Crumling, M.A.; Raphael, Y.; Martin, D.C. Localized cell and drug delivery for auditory prostheses. *Hear. Res.* 2008, 242, 117–131. [CrossRef] [PubMed]

45. Chikar, J.A.; Hendricks, J.L.; Richardson-Burns, S.M.; Raphael, Y.; Pfinggs, B.E.; Martin, D.C. The use of a dual PEDOT and RGD-functionalized alginate hydrogel coating to provide sustained drug delivery and improved cochlear implant function. *Biomaterials* 2012, 33, 1982–1990. [CrossRef]

46. Ashtown, M.D.; Cooper, P.A.; Muniooy, S.; Desimone, M.F.; Chendler, D.; Shnyder, S.D.; Hardy, J.G. Controlled Bioactive Delivery Using Degradable Electroactive Polymers. *Biomacromolecules* 2022, 23, 3031–3040. [CrossRef]

47. Molino, P.J.; Innis, P.C.; Higgins, M.J.; Kapsa, R.M.I.; Wallace, G.G. Influence of biopolymer loading on the physicochemical and electrochemical properties of inherently polymer biomaterials. *Synth. Met.* 2015, 200, 40–47. [CrossRef]

48. Higgins, M.J.; Molino, P.J.; Yue, Z.; Wallace, G.G. Organic Conducting Polymer–Protein Interactions. *Chem. Mater.* 2012, 24, 828–839. [CrossRef]
49. Kim, S.; Jang, Y.; Jang, M.; Lim, A.; Hardy, J.G.; Park, H.S.; Lee, J.Y. Versatile biomimetic conductive polypyrrole films doped with hyaluronic acid of different molecular weights. *Acta Biomater.* 2018, 80, 258–268. [CrossRef]

50. Svirskis, D.; Travas-Sejdic, J.; Rodgers, A.; Garg, S. Electrochemically controlled drug delivery based on intrinsically conducting polymers. *J. Control. Release* 2010, 146, 6–15. [CrossRef]

51. Zhao, J.; Zhao, X.; Guo, B.; Ma, P.X. Multifunctional Interpenetrating Polymer Network Hydrogels Based on Methacrylated Alginote for the Delivery of Small Molecules and Sustained Release of Protein. *Biomacromolecules* 2014, 15, 3246–3252. [CrossRef]

52. Qi, J.; Liang, Y.; Shi, M.; Guo, B.; Gao, Y.; Yin, Z. Biocompatible conductive hydrogels based on dextran and aniline trimer as electro-responsive drug delivery system for localized drug release. *Int. J. Biol. Macromol.* 2019, 140, 255–264. [CrossRef]

53. Qu, J.; Zhao, X.; Ma, P.X.; Guo, B. Injectable antibacterial conductive hydrogels with dual response to an electric field and pH for localized “smart” drug release. *Acta Biomater.* 2018, 72, 55–69. [CrossRef]

54. Zhang, L.; Wang, L.; Guo, B.; Ma, P.X. Cytocompatible injectable carboxymethyl chitosan/N-isopropylacrylamide hydrogels for localized drug delivery. *Carbohydr. Polym.* 2014, 103, 110–118. [CrossRef]

55. Catt, K.; Li, D.X.; Hoang, V.; Beard, R.; Cui, X.T. Self-powered therapeutic release from conducting polymer/graphene oxide films on magnesium. *Nanomed. Nanotechnol. Bio. Med.* 2018, 14, 2495–2503. [CrossRef]

56. Sundararajan, R. *Electroporation-Based Therapies for Cancer, From Basics to Clinical Applications*, 1st ed.; Woodhead Publishing: Cambridge, UK, 2014.

57. Mir, L.M.; Orlowski, S. The Basis of Electrochemotherapy. In *Electrochemotherapy, Electrogenetherapy, and Transdermal Drug Delivery. Methods in Molecular Medicine*; Jaroszski, M.J., Heller, R., Gilbert, R., Eds.; Humana Press: Totowa, NJ, USA, 2000; Volume 37, pp. 99–117.

58. Miklavčič, D.; Mali, B.; Kos, B.; Heller, R.; Serša, G. Electrochemotherapy: From the drawing board into medical practice. *BioMed. Eng. Online* 2014, 13, 29. [CrossRef]

59. Esmaeili, N.; Frieebe, M. Electrochemotherapy: A Review of Current Status, Alternative IGP Approaches, and Future Perspectives. *J. Healthc. Eng.* 2019, 2019, 2784516. [CrossRef]

60. Tellado, M.; Mir, L.M.; Maglietti, F. Veterinary Guidelines for Electrochemotherapy of Superficial Tumors. *Front. Vet. Sci.* 2022, 9, 686989. [CrossRef]

61. Jamsek, C.; Sersa, G.; Bosnjak, M.; Groselj, A. Long term response of electrochemotherapy with reduced dose of bleomycin in elderly patients with head and neck non-melanoma skin cancer. *Radiol. Oncol.* 2020, 54, 79–85. [CrossRef]

62. McMillan, A.; McElroy, L.; O’Toole, L.; Matteucci, P.; Totty, J.P. Electrochemotherapy vs radiotherapy in the treatment of primary cutaneous malignancies or cutaneous metastases from primary solid organ malignancies: A protocol for a systematic review and meta-analysis. *J. Surg. Protoc. Res. Methodol.* 2022, 2022, snac005. [CrossRef]

63. Sersa, G.; Ursica, K.; Cemazar, M.; Heller, R.; Bosnjak, M.; Campana, L.G. Biological factors of the tumour response to electrochemotherapy: Review of the evidence and a research roadmap. *Eur. J. Surg. Oncol.* 2021, 47, 1836–1846. [CrossRef]

64. Sundararajan, R.; Mittal, L.; Camarillo, I.G. Electrochemotherapy Modulates Mammary Tumor Growth in Rats on a Western Diet Supplemented with Curcumin. *Biomedicines* 2020, 8, 498. [CrossRef] [PubMed]

65. Fiorentzis, M.; Katopodis, P.; Kalirai, H.; Seitz, B.; Viestenz, A.; Coupland, S.E. Image Analysis of 3D Conjunctival Melanoma Cell Cultures Following Electrochemotherapy. *Biomedicines* 2020, 8, 158. [CrossRef] [PubMed]

66. Esposito, E.; Siani, C.; Pace, U.; Costanzo, R.; di Giacomo, R. Debubling mastectomy with electrochemotherapy: A case report of no surgery approach to recurrent breast cancer. *Transl. Cancer Res.* 2021, 10, 1144–1149. [CrossRef] [PubMed]

67. Sersa, G.; Stabuc, B.; Cemazar, M.; Miklavčič, D.; Rudolf, Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. *Clin. Cancer Res.* 2000, 6, 863–867.

68. Šatkauskas, S.; Batiuškaitė, D.; Šalomskaitė-Davalgienė, S.; Venslauskas, M.S. Effectiveness of tumor electrochemotherapy as a function of electric pulse strength and duration. *Bioelectrochemistry* 2005, 65, 105–111. [CrossRef]

69. Riva, G.; Salonia, L.; Fassone, E.; Sapino, S.; Piano, F.; Pecorari, G. Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors. *J. Clin. Med.* 2021, 10, 4366. [CrossRef]

70. Rega, D.; Granata, V.; Petrolio, A.; Pace, U.; Di Marzo, M.; Fusco, R.; D’Alessio, V.; Nasti, G.; Romano, C.; Avallone, A.; et al. Electrochemotherapy of Primary Colon Rectum Cancer and Local Recurrence: Case Report and Prospective Analysis. *J. Clin. Med.* 2022, 11, 2745. [CrossRef]

71. Coriat, R.; Pellat, A. Updates on the Treatment of Pancreatic Diseases: Focus on Surgery, Electrochemotherapy and Rituximab. *J. Clin. Med.* 2022, 11, 239. [CrossRef]

72. Izzo, F.; Granata, V.; Fusco, R.; D’Alessio, V.; Petrolio, A.; Lastoria, S.; Piccirillo, M.; Albino, V.; Belli, A.; Nasti, G.; et al. A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer. *J. Clin. Med.* 2021, 10, 4011. [CrossRef]

73. Izzo, F.; Granata, V.; Fusco, R.; D’Alessio, V.; Petrolio, A.; Lastoria, S.; Piccirillo, M.; Albino, V.; Belli, A.; Tafuto, S.; et al. Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy. *J. Clin. Med.* 2021, 10, 1305. [CrossRef]

74. Kaur, G.; Adhikari, R.; Cass, P.; Bown, M.; Gunatillake, P. Electrically conductive polymers and composites for biomedical applications. *RSC Adv.* 2015, 5, 37553–37567. [CrossRef]
102. Manousiouthakis, E.; Park, J.; Hardy, J.G.; Lee, J.Y.; Schmidt, C.E. Towards the translation of electroconductive organic materials for regeneration of neural tissues. Acta Biomater. 2022, 139, 22–42. [CrossRef]

103. Alemdar, N. Synthesis of chitosan-based hydrogel by using photopolymerization technique. Anadolu Univ. J. Sci. Technol. A-App. Sci. Eng. 2016, 17, 391–400. [CrossRef]

104. Bober, P.; Gavrilov, N.; Kovalcik, A.; Mičušík, M.; Unterweger, C.; Paští, I.A.; Šeděnková, I.; Acharya, U.; Pfleger, J.; Filippov, S.K.; et al. Electrochemical properties of lignin/polypyrrole composites and their carbonized analogues. Mater. Chem. Phys. 2018, 213, 352–361. [CrossRef]

105. Uguz, I.; Ganji, M.; Hama, A.; Tanaka, A.; Inal, S.; Youssef, A.; Owens, R.M.; Quilichini, P.P.; Ghestem, A.; Bernard, C.; et al. Autoclave Sterilization of PEDOT:PSS Electrophysiology Devices. Adv. Healthc. Mater. 2016, 5, 3094. [CrossRef]

106. Calleman, C.J. The metabolism and pharmacokinetics of acrylamide: Implications for mechanisms of toxicity and human risk estimation. Drug Metab. Rev. 1996, 28, 527–590. [CrossRef] [PubMed]

107. Edwards, P.M. Neurotoxicity of acrylamide and its analogues and effects of these analogues and other agents on acrylamide peripheral neuropathy. Toxicol. Appl. Pharmacol. 1998, 151, 211–221. [CrossRef] [PubMed]

108. Lehning, E.J.; Persaud, A.; Dyer, K.R.; Jortner, B.S.; LoPachin, R.M. Biochemical and morphologic characterization of acrylamide neuropathy. Toxicol. Appl. Pharmacol. 2006, 211–221. [CrossRef] [PubMed]

109. Foster, R.S.; Fowkes, A.; Cayley, A.; Thresher, A.; Werner, A.D.; Barber, C.G.; Kocks, G.; Tennant, R.E.; Williams, R.V.; Kane, S.; et al. The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7. Genes Environ. 2020, 42, 27. [CrossRef] [PubMed]

110. Foster, R.S.; Fowkes, A.; Cayley, A.; Thresher, A.; Werner, A.D.; Barber, C.G.; Kocks, G.; Tennant, R.E.; Williams, R.V.; Kane, S.; et al. The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7. Genes Environ. 2020, 42, 27. [CrossRef] [PubMed]

111. Cellink. Available online: https://www.cellink.com/wp-content/uploads/2019/07/Irgacure-2959-SDS-12-July-2019.pdf (accessed on 4 September 2022).

112. Macmillan, D.S.; Chilton, M.L. A defined approach for predicting skin sensitisation hazard and potency based on the guided integration of in silico, in chemico and in vitro data using exclusion criteria. Regul. Toxicol. Pharmacol. 2019, 101, 35–47. [PubMed]

113. Calleman, C.J. The metabolism and pharmacokinetics of acrylamide: Implications for mechanisms of toxicity and human risk estimation. Drug Metab. Rev. 1996, 28, 527–590. [CrossRef] [PubMed]

114. Calleman, C.J. The metabolism and pharmacokinetics of acrylamide: Implications for mechanisms of toxicity and human risk estimation. Drug Metab. Rev. 1996, 28, 527–590. [CrossRef] [PubMed]

115. Edwards, P.M. Neurotoxicity of acrylamide and its analogues and effects of these analogues and other agents on acrylamide peripheral neuropathy. Toxicol. Appl. Pharmacol. 1998, 151, 211–221. [CrossRef] [PubMed]

116. Unagolla, J.M.; Jayasuriya, A.C. Hydrogel-based 3D bioprinting: A comprehensive review on cell-laden hydrogels, bioink formulations, and future perspectives. Appl. Mater. Today. 2020, 18, 100479. [CrossRef]

117. Crofton, K.M.; Padilla, S.; Tilson, H.A.; Anthony, D.C.; Raymer, J.H.; MacPhail, R.C. The impact of dose rate on the neurotoxicity of acrylamide: The interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Toxicol. Appl. Pharmacol. 1996, 139, 163–176. [CrossRef]

118. Crofton, K.M.; Padilla, S.; Tilson, H.A.; Anthony, D.C.; Raymer, J.H.; MacPhail, R.C. The impact of dose rate on the neurotoxicity of acrylamide: The interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Toxicol. Appl. Pharmacol. 1996, 139, 163–176. [CrossRef]

119. Edwards, P.M. Neurotoxicity of acrylamide and its analogues and effects of these analogues and other agents on acrylamide neuropathy. Br. J. Ind. Med. 1975, 32, 31–38.

120. Edwards, P.M. Neurotoxicity of acrylamide and its analogues and effects of these analogues and other agents on acrylamide neuropathy. Br. J. Ind. Med. 1975, 32, 31–38.